Skip to main content
SpringerLink
Log in
Birkhäuser

Pharmacotherapy of Obesity

  • Book
  • © 2008

Overview

Editors:
  1. John P. H. Wilding

    1. Clinical Sciences Centre, University Hospital Aintree, Liverpool, UK

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  • Discusses the drugs approved for long-term use in the treatment of obesity
  • Excellent overview on the topic
  • International authorship
  • Includes supplementary material: sn.pub/extras

Part of the book series: Milestones in Drug Therapy (MDT)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (8 chapters)

  1. Front Matter

    Pages I-X
    Download chapter PDF

  2. Why drugs?

    • F. Xavier Pi-Sunyer
    Pages 1-10

  3. Some historical aspects of drug treatment for obesity

    • George A. Bray
    Pages 11-19

  4. Regulation of energy balance — towards rational drug design in obesity

    • Joanne A. Harrold, John P. H. Wilding
    Pages 21-46

  5. Intestinal lipase inhibitors

    • John P. H. Wilding
    Pages 47-57

  6. Sibutramine

    • John P. H. Wilding
    Pages 59-68

  7. The endocannabinoid system as a target for obesity treatment

    • Muhammad Khan, John P. H. Wilding
    Pages 69-80

  8. Using the body’s natural signals — gut hormones

    • Owais B. Chaudhri, Kirsty L. Smith, Stephen R. Bloom
    Pages 81-99

  9. Influencing energy expenditure and substrate utilisation

    • John C. Clapham, Jonathan R. Arch
    Pages 101-115

  10. Back Matter

    Pages 117-120
    Download chapter PDF
Back to top

Keywords

About this book

Obesity has become a major epidemic that now rivals smoking as a risk to public health. The ensuing epidemics of diabetes, vascular disease and other complications are set to overwhelm the healthcare systems of wealthy and poorer nations alike. The need for effective pharmacotherapy has never been greater. This book takes a new look at the many potential targets for drug development for regulation of body weight, placing them in the context of the chequered history of drug development for obesity and currently available therapies.

Potential peripheral and central nervous system targets are discussed in detail by authors with extensive knowledge and research experience in the science of body weight regulation, and its translation into effective therapies that will benefit patients. This book is of interest to clinicians, researchers in the field and members of the pharmaceutical industry who are interested in learning more about the current state of the art and future directions in the pharmacotherapy of obesity.

Reviews

From the reviews:

“This book attempts to give a clear update of this obesity research and is readily accessible to healthcare professionals. … This is a welcome update to the field of obesity research and will be of use to healthcare professional and researchers … .” (Steven T. Russell, Inflammopharmacology, Vol. 18, 2010)

Editors and Affiliations

  • Clinical Sciences Centre, University Hospital Aintree, Liverpool, UK

    John P. H. Wilding

Bibliographic Information

Publish with us

Policies and ethics

Back to top

Search

Navigation